Jazz Pharma buys the only shot at a disease with no FDA treatment
Covered by 1 source · 1 article
Jazz Pharmaceuticals (JAZZ) just made a bet on a disease that many investors have never heard of. On August 10, the drugmaker agreed to buy privately held Actio Biosciences. The prize is an experimental medicine aimed at a childhood epileps…
Covered by
